Numerous ongoing clinical trials are investigating various GLP-1R agonist analogs, including exenatide, liraglutide, semaglutide, and lixisenatide, as anti-neurodegenerative agents in AD and PD patients [46,47]. The gene discussed is GLP1R; the disease is Alzheimer disease.